Jennifer A. Woyach

Dr. Jennifer A. Woyach

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2018 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
JWJennifer A. Woyach
Jennifer A. Woyach
ARAmy S. Ruppert
Amy S. Ruppert
NHNyla A. Heerema
Nyla A. Heerema
WZWeiqiang Zhao
Weiqiang Zhao
ABAllison M. Booth
Allison M. Booth
JBJohn C. Byrd
John C. Byrd
Ibrutinib has been approved by the Food and Drug Administration for the treatment of patients with untreated chronic lymphocytic leukemia (CLL) since 2016 but has not been compared with chemoimmunotherapy. We conducted a phase 3 trial to evaluate the efficacy of ibrutinib, either alone or in combination with rituximab, relative to chemoimmunotherapy. Patients 65 years of age or older who had untreated CLL were randomly assigned to receive bendamustine plus rituximab, ibrutinib, or ibrutinib plus rituximab. The primary end point was progression-free survival. The Alliance Data and Safety Monitoring Board made the decision to release the data after the protocol-specified efficacy threshold had been met. A total of 183 patients were assigned to receive bendamustine plus rituximab, 182 to receive ibrutinib, and 182 to receive ibrutinib plus rituximab. Median progression-free survival was reached only with bendamustine plus rituximab. The estimated percentage of patients with progression-free survival at 2 years was 74% with bendamustine plus rituximab and was higher with ibrutinib alone (87%; hazard ratio for disease progression or death, 0.39; 95% confidence interval [CI], 0.26 to 0.58; P<0.001) and with ibrutinib plus rituximab (88%; hazard ratio, 0.38; 95% CI, 0.25 to 0.59; P<0.001). There was no significant difference between the ibrutinib-plus-rituximab group and the ibrutinib group with regard to progression-free survival (hazard ratio, 1.00; 95% CI, 0.62 to 1.62; P=0.49). With a median follow-up of 38 months, there was no significant difference among the three treatment groups with regard to overall survival. The rate of grade 3, 4, or 5 hematologic adverse events was higher with bendamustine plus rituximab (61%) than with ibrutinib or ibrutinib plus rituximab (41% and 39%, respectively), whereas the rate of grade 3, 4, or 5 nonhematologic adverse events was lower with bendamustine plus rituximab (63%) than with the ibrutinib-containing regimens (74% with each regimen). Among older patients with untreated CLL, treatment with ibrutinib was superior to treatment with bendamustine plus rituximab with regard to progression-free survival. There was no significant difference between ibrutinib and ibrutinib plus rituximab with regard to progression-free survival. (Funded by the National Cancer Institute and Pharmacyclics; ClinicalTrials.gov number, NCT01886872.)

1 April 2015 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
KMKami J. Maddocks
Kami J. Maddocks
ARAmy S. Ruppert
Amy S. Ruppert
GLGerard Lozanski
Gerard Lozanski
NHNyla A. Heerema
Nyla A. Heerema
WZWeiqiang Zhao
Weiqiang Zhao
JWJennifer A. Woyach
Jennifer A. Woyach
Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia in adults and is not considered curable outside of allogeneic stem cell transplantation. Significant advances have been made in the therapy, notably the emergence of kinase inhibitors for patients with relapsed disease. Prior to US Food and Drug Administration (FDA) approval of ibrutinib and idelalisib with rituximab, standard therapy for relapsed CLL could be expected to induce response rates of 30% to 50%1-3 and progression-free survival (PFS) of generally less than 1 year. The phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3 kinase) delta isoform inhibitor idelalisib4,5 and Bruton tyrosine kinase (BTK) inhibitor ibrutinib have significantly improved the outcomes for these patients.

1 May 2017 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JWJennifer A. Woyach
Jennifer A. Woyach
ARAmy S. Ruppert
Amy S. Ruppert
DGDaphne Guinn
Daphne Guinn
ALAmy Lehman
Amy Lehman
JBJames S. Blachly
James S. Blachly
JBJohn C. Byrd
John C. Byrd
Purpose: Therapeutic targeting of Bruton tyrosine kinase (BTK) with ibrutinib in chronic lymphocytic leukemia has led to a paradigm shift in therapy, and relapse has been uncommon with current follow-up. Acquired mutations in BTK and PLCG2 can cause relapse, but data regarding the prevalence and natural history of these mutations are limited. Patients and Methods: Patients accrued to four sequential studies of ibrutinib were included in these analyses. Deep sequencing for BTK and PLCG2 was performed retrospectively on patients who experienced relapse and prospectively on a screening population. Results: With a median follow-up time of 3.4 years, the estimated cumulative incidence of progression at 4 years is 19% (95% CI, 14% to 24%). Baseline karyotypic complexity, presence of del(17)(p13.1), and age less than 65 years were risk factors for progression. Among patients who experienced relapse, acquired mutations of BTK or PLCG2 were found in 85% (95% CI, 71% to 94%), and these mutations were detected an estimated median of 9.3 months (95% CI, 7.6 to 11.7 months) before relapse. Of a group of 112 patients examined prospectively, eight patients have experienced relapse, and all of these patients had acquired resistance mutations before relapse. A resistance mutation was detected in an additional eight patients who have not yet met criteria for clinical relapse. Conclusion: Relapse of chronic lymphocytic leukemia after ibrutinib is an issue of increasing clinical significance. We show that mutations in BTK and PLCG2 appear early and have the potential to be used as a biomarker for future relapse, suggesting an opportunity for intervention.

20 March 2014 in Blood
Verified
Journal Article
Open access
PDF file
JWJennifer A. Woyach
Jennifer A. Woyach
KSKelly Smucker
Kelly Smucker
LSLisa L. Smith
Lisa L. Smith
ALArletta Lozanski
Arletta Lozanski
YZYiming Zhong
Yiming Zhong
JBJohn C. Byrd
John C. Byrd
Key Points: Persistent CLL cells during ibrutinib therapy show evidence of biochemical activation, but inhibited BCR and no proliferation. Long lymphocytosis during ibrutinib therapy is not associated with adverse progression-free survival.

1 January 2022 in Leukemia
Verified
Journal Article
Open access
PDF file
JSJeff P. Sharman
Jeff P. Sharman
MEMiklos Egyed
Miklos Egyed
WJWojciech Jurczak
Wojciech Jurczak
ASAlan Skarbnik
Alan Skarbnik
JPJohn M. Pagel
John M. Pagel
JBJohn C. Byrd
John C. Byrd

24 August 2023 in Blood
Verified
Journal Article
Open access
PDF file
JSJohn Seymour
John Seymour
JBJohn C. Byrd
John C. Byrd
PGPaolo Prospero Ghia
Paolo Prospero Ghia
AKArnon P. Kater
Arnon P. Kater
ACAsher Chanan-Khan
Asher Chanan-Khan
JWJennifer A. Woyach
Jennifer A. Woyach
ELEVATE-RR demonstrated noninferior progression-free survival and lower incidence of key adverse events (AEs) with acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia. We further characterize AEs of acalabrutinib and ibrutinib via post hoc analysis. Overall and exposure-adjusted incidence rate was assessed for common Bruton tyrosine kinase inhibitor–associated AEs and for selected events of clinical interest (ECIs). AE burden scores based on previously published methodology were calculated for AEs overall and selected ECIs. Safety analyses included 529 patients (acalabrutinib, n = 266; ibrutinib, n = 263). Among common AEs, incidences of any-grade diarrhea, arthralgia, urinary tract infection, back pain, muscle spasms, and dyspepsia were higher with ibrutinib, with 1.5- to 4.1-fold higher exposure-adjusted incidence rates. Incidences of headache and cough were higher with acalabrutinib, with 1.6- and 1.2-fold higher exposure-adjusted incidence rate, respectively. Among ECIs, incidences of any-grade atrial fibrillation/flutter, hypertension, and bleeding were higher with ibrutinib, as were exposure-adjusted incidence rates (2.0-, 2.8-, and 1.6-fold, respectively); incidences of cardiac events overall (the Medical Dictionary for Regulatory Activities system organ class) and infections were similar between arms. Rate of discontinuation because of AEs was lower for acalabrutinib (hazard ratio, 0.62; 95% confidence interval, 0.41-0.93). AE burden score was higher for ibrutinib vs acalabrutinib overall and for the ECIs atrial fibrillation/flutter, hypertension, and bleeding. A limitation of this analysis is its open-label study design, which may influence the reporting of more subjective AEs. Overall, event-based analyses and AE burden scores demonstrated higher AE burden overall and specifically for atrial fibrillation, hypertension, and hemorrhage with ibrutinib vs acalabrutinib. This trial was registered at www.clinicaltrials.gov as #NCT02477696.